345883
GGTI-298 - CAS 180977-44-0 - Calbiochem
Synonym(s):
N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-Leucine methyl ester, TFA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
General description
A cell-permeable, prodrug form of the GGTase I inhibitor GGTI-297 (Cat. No. 345882). Inhibits the processing of Rap 1A (IC50 = 3 μM) but had no effect on the processing of H-Ras even at concentrations of 15 μM. Also arrests cells in the G0/G1 phase of the cell cycle, induces apoptosis and enhances nitric oxide synthase-2 induction by IL-1β.
A cell-permeable, prodrug form of the GGTase I inhibitor GGTI-297 (Cat. No. 345882). Inhibits the processing of Rap 1A (IC50 = 3 μM) but has no effect on the processing of H-Ras even at concentrations of 15 μM. Inhibits PDGF-receptor tyrosine phosphorylation. Also arrests cells in the G0/G1 phase of the cell cycle, induces apoptosis, and enhances iNOS induction by IL-1β.
A cell-permeable, prodrug form of the GGTase I inhibitor GGTI-297.
Biochem/physiol Actions
Target IC50:3 μM against processing of Rap 1A
Physical form
Supplied as a trifluoroacetate salt.
Reconstitution
Degas DMSO just prior to reconstitution
Following reconstitution, aliquot and freeze (-20°C). Unstable in solution; reconstitute just prior to use.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A Vogt et al.
The Journal of biological chemistry, 272(43), 27224-27229 (1997-10-27)
Recently we have shown that in fibroblasts (NIH 3T3 and Rat-1 cells) inhibition of protein geranylgeranylation leads to a G0/G1 arrest, whereas inhibition of protein farnesylation does not affect cell cycle distribution. Here we demonstrate that in human tumor cells
J D Finder et al.
The Journal of biological chemistry, 272(21), 13484-13488 (1997-05-23)
Recently, we have designed farnesyltransferase and geranylgeranyltransferase I inhibitors (FTI-277 and GGTI-298) that selectively block protein farnesylation and geranylgeranylation, respectively. In this study, we describe the opposing effects of these inhibitors on interleukin-1beta (IL-1beta)-stimulated induction of nitric-oxide synthase-2 (NOS-2) in
K Miquel et al.
Cancer research, 57(10), 1846-1850 (1997-05-15)
The mechanism by which the geranylgeranyltransferase I inhibitor GGTI-298 and the farnesyltransferase inhibitor FTI-277 inhibit human tumor growth is not known. Herein, we demonstrate that in the human lung adenocarcinoma A549 cells, GGTI-298 induced a G1-G0 block whereas FTI-277 induced
T F McGuire et al.
The Journal of biological chemistry, 271(44), 27402-27407 (1996-11-01)
We have used specific inhibitors for farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) I as well as combinations of lovastatin with geranylgeraniol (GGOH) or farnesol (FOH) to investigate the role of protein prenylation in platelet-derived growth factor (PDGF)-induced PDGF receptor tyrosine phosphorylation.
Y Qian et al.
Bioorganic & medicinal chemistry, 6(3), 293-299 (1998-05-06)
In this paper we describe the synthesis of a family of CAAL peptidomimetics as GGTase-I inhibitors. These inhibitors lack the central dipeptide AA in the key CAAL carboxy terminal sequence of geranylgeranylated proteins and are more selective for GGTase-I over
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
